FDA, EU Probing Carcinogen Detected in Versions of Zantac
Health officials in the U.S. and Europe are looking into the popular heartburn medication Zantac and its generic versions after a carcinogen was found in the drugs, the same contaminant that sparked a worldwide recall of blood-pressure pills beginning last year, Bloomberg News reports.
Drug regulators said Friday they are looking at whether ranitidine medications contain levels of the probable carcinogen NDMA that could pose a danger to patients. The review comes after an online pharmacy that tests every drug it dispenses alerted the U.S. Food and Drug Administration to findings of high levels of the compound in generic and name-brand versions of Zantac sold at major pharmacies operated by companies including Walgreens Boots Alliance Inc., CVS Health Corp. and Walmart Inc.
https://www.bloomberg.com/news/articles/2019-09-13/health-officials-probe-carcinogen-found-in-versions-of-zantac